In vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus

Journal of Antibiotics

Volumn 59, Issue 2, 2006, Pages 80-85

  Osburne, Marcia S ^a,b   Rothstein, David M ^a   Farquhar, Ronnie ^a,c   Murphy, Christopher K ^a  

^a ActivBiotics Inc   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

Combination treatment; Rifampicin; Time kill assay; Vancomycin

Indexed keywords

RIFALAZIL; RIFAMPICIN; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CELL DEATH; CELL DENSITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE; MICROBIAL SENSITIVITY TESTS; RIFAMYCINS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; VANCOMYCIN;

BACTERIA (MICROORGANISMS); PROKARYOTA; STAPHYLOCOCCUS AUREUS;

EID: 33645764164     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2006.11     Document Type: Article

References (10)

1. Rothstein DM, Hartman AD, Cynamon M, Eisenstein BI. Development potential of Rifalazil. Expert Opin Investig Drugs 12: 1-17 (2003)
2. Morse R, O'Hanlon K, Collins MD. Phylogenetic, amino acid content and indel analyses of the beta subunit of DNA-dependent RNA polymerase of Gram-positive and Gram-negative bacteria. Int J Syst Evol Microbiol 52 (Pt 5): 1477-1484 (2002)
3. Bayer AS, Morrison JO. Disparity between time-killed and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampicin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother 26: 220-223 (1984)
4. Palmer SM, Rybak MJ. Pharmacodynamics of once- or twice- daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob Agents Chemother 40: 701-705 (1996)
5. Schierholz JM, Beuth J, Pulverer G. Killing effects of antibiotics and two-fold antimicrobial combinations on proliferating and non growing staphylococci. Zentralbl Bacteriol 288: 527-539 (1998)
6. Fujii K, Tsuji A, Miyazaki S, Yamaguchi K, Goto S. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrob Agents Chemother 38: 1118-1122 (1994)
7. Pearson RD, Seigbigel RT, Davis HT, Chapman S. Method for reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother 18: 699-708 (1980)
8. Krogstad DJ, Moellering RC. Antimicrobial combinations. In: Lorian y ed. Antibiotics in laboratory medicine, 2nd ed. Baltimore MD: Williams & Wilkins Co, pp. 537-595 (1986)
9. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17 (2003)
10. Shelburne SA, Musher DM, Hulten K, Ceasar H, Lu MY, Bhaila I, Hamill RJ. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 48: 4016-4019 (2004)